Multivalent FAPI-based radiopharmaceuticals in PET/CT: from cancer diagnostics to theranostics.

IF 2 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

American journal of nuclear medicine and molecular imaging Pub Date : 2025-04-15 eCollection Date: 2025-01-01 DOI:10.62347/TUZI7617

Taoqian Zhao, Steven H Liang

引用次数: 0

Abstract

Radiopharmaceuticals targeting fibroblast activation protein (FAP) have rapidly emerged as innovative agents for cancer imaging and therapy. By selectively binding to cancer-associated fibroblasts (CAFs), radiolabeled FAP inhibitors (FAPIs) enable high-contrast PET/CT imaging across diverse tumor types. This article highlights recent advances in FAPI PET/CT imaging, with particular focus on the influence of multivalency effect in radiotracer development.

查看原文本刊更多论文

PET/CT中基于多价fapi的放射性药物：从癌症诊断到治疗。

靶向成纤维细胞活化蛋白（FAP）的放射性药物已迅速成为癌症成像和治疗的创新药物。通过选择性结合癌症相关成纤维细胞（CAFs），放射性标记FAP抑制剂（FAPIs）可以实现不同肿瘤类型的高对比度PET/CT成像。本文重点介绍了FAPI PET/CT成像的最新进展，特别是多价效应在放射性示踪剂开发中的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American journal of nuclear medicine and molecular imaging RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-

自引率

4.00%

发文量

期刊介绍： The scope of AJNMMI encompasses all areas of molecular imaging, including but not limited to: positron emission tomography (PET), single-photon emission computed tomography (SPECT), molecular magnetic resonance imaging, magnetic resonance spectroscopy, optical bioluminescence, optical fluorescence, targeted ultrasound, photoacoustic imaging, etc. AJNMMI welcomes original and review articles on both clinical investigation and preclinical research. Occasionally, special topic issues, short communications, editorials, and invited perspectives will also be published. Manuscripts, including figures and tables, must be original and not under consideration by another journal.